Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
20 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will...